Business Description
Arcinova is a Contract Research and Development Organisation (CRDO), providing a comprehensive range of integrated specialist services, backed by extensive scientific expertise and strong practical capabilities.
Arcinova provides both integrated end to end solutions and standalone services to pharmaceutical and biotech companies across the globe. It’s offerings include drug substance synthesis, drug product manufacture, Chemistry, Manufacturing and Controls (CMC), bioanalytical and metabolism services, radiolabelling synthesis and synthesis of toxic/highly potent APIs.
Arcinova recently announced the award of a £1.5m INNOVATE UK grant for the development of new flexible modular manufacturing technologies, a project which is set to demonstrate the operating feasibility of world first innovative continuous production tools. … three-year period …in collaboration with the UNIVERSITY OF NOTTINGHAM.
Arcinova has been spearheading the use of new intensive manufacturing technology processes to support the rapid development of pioneering drugs for the treatment of life-threating illnesses including cancer.
As a result of its innovative approach, Arcinova has more than doubled its customer base to 125 in the past two years, generating revenue of close to £9m.
Arcinova was founded in 2016 by serial entrepreneurs, Professor Ian Shott CBE (CEO), and Paul Ryan (CFO), after the acquisition of a 15,000m2 contract research facility in Alnwick, on a 34-acre site, which has benefited from decades of investment as a key research and development centre for SANOFI and COVANCE.
Professor Shott is visiting Professor at Nottingham, Newcastle and Oxford Universities.
3 July 2018. Arcinova has appointed a new Chief Scientific Officer to further accelerate the company's growth. Dr Gareth Jenkins CChem FRSC has joined Arcinova from BRITEST, a manufacturing process consultancy, where he was CEO.
19 June 2018 - BGF has invested £5 million growth capital in Arcinova.
BGF, a £2.5 billion investment company, will provide support as a long-term minority shareholder in the business. The initial funding will be used for further investment in the joint-project, as well as new equipment, infrastructure and people in the UK and overseas to further increase capacity. Arcinova were advised by WOMBLE BOND DICKINSON.
Following an introduction by BGF, Arcinova has appointed Mike Hudson, co-founder of NEUROPHARM, as non-executive Chair.
Arcinova provides both integrated end to end solutions and standalone services to pharmaceutical and biotech companies across the globe. It’s offerings include drug substance synthesis, drug product manufacture, Chemistry, Manufacturing and Controls (CMC), bioanalytical and metabolism services, radiolabelling synthesis and synthesis of toxic/highly potent APIs.
Arcinova recently announced the award of a £1.5m INNOVATE UK grant for the development of new flexible modular manufacturing technologies, a project which is set to demonstrate the operating feasibility of world first innovative continuous production tools. … three-year period …in collaboration with the UNIVERSITY OF NOTTINGHAM.
Arcinova has been spearheading the use of new intensive manufacturing technology processes to support the rapid development of pioneering drugs for the treatment of life-threating illnesses including cancer.
As a result of its innovative approach, Arcinova has more than doubled its customer base to 125 in the past two years, generating revenue of close to £9m.
Arcinova was founded in 2016 by serial entrepreneurs, Professor Ian Shott CBE (CEO), and Paul Ryan (CFO), after the acquisition of a 15,000m2 contract research facility in Alnwick, on a 34-acre site, which has benefited from decades of investment as a key research and development centre for SANOFI and COVANCE.
Professor Shott is visiting Professor at Nottingham, Newcastle and Oxford Universities.
3 July 2018. Arcinova has appointed a new Chief Scientific Officer to further accelerate the company's growth. Dr Gareth Jenkins CChem FRSC has joined Arcinova from BRITEST, a manufacturing process consultancy, where he was CEO.
19 June 2018 - BGF has invested £5 million growth capital in Arcinova.
BGF, a £2.5 billion investment company, will provide support as a long-term minority shareholder in the business. The initial funding will be used for further investment in the joint-project, as well as new equipment, infrastructure and people in the UK and overseas to further increase capacity. Arcinova were advised by WOMBLE BOND DICKINSON.
Following an introduction by BGF, Arcinova has appointed Mike Hudson, co-founder of NEUROPHARM, as non-executive Chair.
Registered Address
C/O Quotient Sciences Limited Trent House Mere Way, Ruddington Fields Business Park
Ruddington
Nottingham
NG11 6JS
Ruddington
Nottingham
NG11 6JS
Contact Details
- Web -
- http://arcinova.uk/
Previous Names
| Name | Period |
|---|---|
| TRINOVA BIOPHARM LIMITED | 2015-11-26 - 2015-12-04 |
| CROSSCO (1405) LIMITED | 2015-09-08 - 2015-11-26 |
Key Data
- Sector
- 4573 Biotechnology
- Company Number
- 09767194
- Type
- Private Limited Company
- Company Age
- 5 years
- Incorporated
- September 8, 2015
- Status
- Active
- Nature of Business
- 72110 - Research and experimental development on biotechnology
- Year End
- December 31
- Accounts Due
- September 30, 2021
- Latest Accounts
- December 31, 2019
